Evolent Health price target lowered to $44 from $45 at Canaccord

Canaccord lowered the firm’s price target on Evolent Health to $44 from $45 and keeps a Buy rating on the shares. The firm adjusted itsestimates for 2024 and 2025 to better reflect Evolent’s gross margin trajectory and in the current challenging environment for payers, Canaccord is confident the company can generate the necessary business to meet its objectives.